Evogene, Systasy and LMU Launch EUREKA-Funded Neutrophil-Targeting Therapy Collaboration
Evogene, Systasy Bioscience and LMU University Hospital Munich secured a pan-European EUREKA grant to jointly develop small-molecule therapies targeting neutrophil-driven hyper-inflammatory diseases such as inflammatory bowel disease. The program integrates Evogene’s ChemPass AI design engine, Systasy’s DNA barcoding PathwayProfiler and LMU’s stem cell models for preclinical validation.
1. Collaboration Overview
Evogene Ltd., Systasy Bioscience and LMU University Hospital Munich have formed a partnership supported by a pan-European EUREKA grant to accelerate discovery of therapies for neutrophil-driven inflammatory diseases including inflammatory bowel disease.
2. Evogene’s ChemPass AI Platform
Evogene will lead the small-molecule design effort using its proprietary ChemPass AI generative engine to design, optimize and prioritize novel inhibitors targeting excessive neutrophil activation, with integrated high-throughput experimental validation in collaboration with the Weizmann Institute of Science.
3. Systasy and LMU Contributions
Systasy Bioscience will apply its DNA barcoding PathwayProfiler platform for hyper-multiplexed functional profiling of patient-derived neutrophils, while LMU’s Department of Pediatrics will validate lead compounds in advanced stem cell–derived neutrophil models and support biomarker discovery.
4. Funding and Next Steps
The EUREKA grant enables pan-European collaboration across Israel and Germany, with the teams planning to advance validated compounds into in vivo studies and lay the foundation for future clinical development.